Lee Hambright
Stock Analyst at Bernstein
(2.85)
# 2,476
Out of 5,182 analysts
40
Total ratings
46.67%
Success rate
0.07%
Average return
Main Sectors:
Stocks Rated by Lee Hambright
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PODD Insulet | Maintains: Outperform | $380 → $330 | $189.56 | +74.09% | 3 | Feb 19, 2026 | |
| ABT Abbott Laboratories | Maintains: Outperform | $154 → $125 | $91.13 | +37.17% | 7 | Jan 23, 2026 | |
| ISRG Intuitive Surgical | Maintains: Outperform | $740 → $750 | $482.22 | +55.53% | 4 | Jan 23, 2026 | |
| MDLN Medline | Initiates: Outperform | $49 | $44.76 | +9.47% | 1 | Jan 12, 2026 | |
| ZBH Zimmer Biomet Holdings | Maintains: Market Perform | $97 → $99 | $91.26 | +8.48% | 2 | Jan 9, 2026 | |
| TNDM Tandem Diabetes Care | Maintains: Market Perform | $18 → $25 | $20.36 | +22.79% | 2 | Jan 9, 2026 | |
| SYK Stryker | Maintains: Outperform | $450 → $465 | $327.51 | +41.98% | 4 | Jan 9, 2026 | |
| MDT Medtronic | Maintains: Outperform | $111 → $112 | $83.32 | +34.42% | 4 | Jan 9, 2026 | |
| JNJ Johnson & Johnson | Maintains: Market Perform | $193 → $208 | $227.50 | -8.57% | 6 | Jan 9, 2026 | |
| DXCM DexCom | Maintains: Outperform | $84 → $86 | $61.57 | +39.68% | 3 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $92 → $100 | $62.07 | +61.11% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $132 → $135 | $84.15 | +60.43% | 3 | Mar 16, 2022 |
Insulet
Feb 19, 2026
Maintains: Outperform
Price Target: $380 → $330
Current: $189.56
Upside: +74.09%
Abbott Laboratories
Jan 23, 2026
Maintains: Outperform
Price Target: $154 → $125
Current: $91.13
Upside: +37.17%
Intuitive Surgical
Jan 23, 2026
Maintains: Outperform
Price Target: $740 → $750
Current: $482.22
Upside: +55.53%
Medline
Jan 12, 2026
Initiates: Outperform
Price Target: $49
Current: $44.76
Upside: +9.47%
Zimmer Biomet Holdings
Jan 9, 2026
Maintains: Market Perform
Price Target: $97 → $99
Current: $91.26
Upside: +8.48%
Tandem Diabetes Care
Jan 9, 2026
Maintains: Market Perform
Price Target: $18 → $25
Current: $20.36
Upside: +22.79%
Stryker
Jan 9, 2026
Maintains: Outperform
Price Target: $450 → $465
Current: $327.51
Upside: +41.98%
Medtronic
Jan 9, 2026
Maintains: Outperform
Price Target: $111 → $112
Current: $83.32
Upside: +34.42%
Johnson & Johnson
Jan 9, 2026
Maintains: Market Perform
Price Target: $193 → $208
Current: $227.50
Upside: -8.57%
DexCom
Jan 9, 2026
Maintains: Outperform
Price Target: $84 → $86
Current: $61.57
Upside: +39.68%
Oct 24, 2024
Maintains: Outperform
Price Target: $92 → $100
Current: $62.07
Upside: +61.11%
Mar 16, 2022
Upgrades: Outperform
Price Target: $132 → $135
Current: $84.15
Upside: +60.43%